Michael Barbella, Managing Editor07.20.23
Robocath has unveiled a robotic solution that allows interventional cardiologists to perform coronary angioplasties by controlling devices using an integrated control command unit located in the cathlab or in the control room.
R-One+ benefits cardiologists in two ways: First, the system protects the physician and medical team against radiation-induced injuries, and second, it makes the PCI procedure easier and safer. R-One+ enables cardiologists to perform enhanced hand gestures with even greater precision and in more comfortable working conditions, all of which benefits the patient.
“For the first time, I was able to perform several robotic angioplasties from the comfort of my chair in the control room, where I was completely shielded from X-rays and could dispense with my lead apron. I also benefited from the excellent visibility on the radioscopy and hemodynamic monitoring screens," said Dr. Mohammed Nejjari, interventional cardiologist at the Centre Cardiologique du Nord (CCN) in Saint-Denis, France. "This new set-up has changed the way we organize our procedures and has given nursing staff the opportunity to develop new skills. This new approach has also enabled doctors to shift their focus back to their core activities and to perform procedures in complete safety and with millimeter precision. I’m excited to incorporate this new robotic technology into my day-to-day work. Without doubt, it opens up some new and extremely promising avenues for the treatment of cardiovascular diseases, especially in the case of long and complex procedures.”
“R-One+ makes it extremely easy to position devices with millimeter precision. It’s also much more comfortable to operate using robotic technology, and, as the prinicipal operator, I am completely protected from radiation. I firmly believe that robotics has a major role to play in the transformation of interventional cardiology and the use of this technology will mark a new chapter in the history of our field,” said Prof. Michael Haude, interventional cardiologist at the Lukaskrankenhaus hospital in Neuss, Germany.
“The launch of R-One+ shows what our company is all about—listening to our users’ needs and fostering exceptional partnerships between our different units in order to produce the best possible results for physicians. I would like to thank the medical community for giving their time so willingly and for their excellent advice," Robocath CEO Lucien Goffart stated. "I would also like to thank all our staff who have worked so hard to launch this new robotic platform and, in doing so, taken us one step further on our roadmap to greater commercial success.”
“Robotic technology is digitizating endovascular medicine. I’m delighted that we are now launching R-One+; this solution marks a major step forward in the digital transformation of the cathlab as we continue to work towards our goal of ensuring better care for patients and better protection for medical staff,” Robocath President/Founder Philippe Bencteux, M.D., said.
Founded in 2009 by Bencteux, Robocath designs, develops, and commercializes smart robotic solutions to treat cardiovascular diseases. As an active player in the digital evolution of the medical industry, its smart connected solutions aim to enhance hand gestures and make medical procedures safer. Robocath develops robotic solutions integrating a unique bionic technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. Robocath’s robotic solutions are designed to operate with precision and perform accurate movements, creating better interventional conditions. Thanks to their open architecture, they are all compatible with market-leading devices and cathlabs.
The company received the CE marking for R-One, its first robotic solution, in 2019. In a prospective, multicenter, non-randomized, single-arm clinical trial, R-One demonstrated safety and efficacy as it achieved more than 95% technical procedure success with no MACE (major adverse cardiovascular events). Currently R-One is used in Europe, Africa, and China. Based in Rouen, France, Robocath has more than 70 employees.
R-One+ benefits cardiologists in two ways: First, the system protects the physician and medical team against radiation-induced injuries, and second, it makes the PCI procedure easier and safer. R-One+ enables cardiologists to perform enhanced hand gestures with even greater precision and in more comfortable working conditions, all of which benefits the patient.
“For the first time, I was able to perform several robotic angioplasties from the comfort of my chair in the control room, where I was completely shielded from X-rays and could dispense with my lead apron. I also benefited from the excellent visibility on the radioscopy and hemodynamic monitoring screens," said Dr. Mohammed Nejjari, interventional cardiologist at the Centre Cardiologique du Nord (CCN) in Saint-Denis, France. "This new set-up has changed the way we organize our procedures and has given nursing staff the opportunity to develop new skills. This new approach has also enabled doctors to shift their focus back to their core activities and to perform procedures in complete safety and with millimeter precision. I’m excited to incorporate this new robotic technology into my day-to-day work. Without doubt, it opens up some new and extremely promising avenues for the treatment of cardiovascular diseases, especially in the case of long and complex procedures.”
“R-One+ makes it extremely easy to position devices with millimeter precision. It’s also much more comfortable to operate using robotic technology, and, as the prinicipal operator, I am completely protected from radiation. I firmly believe that robotics has a major role to play in the transformation of interventional cardiology and the use of this technology will mark a new chapter in the history of our field,” said Prof. Michael Haude, interventional cardiologist at the Lukaskrankenhaus hospital in Neuss, Germany.
“The launch of R-One+ shows what our company is all about—listening to our users’ needs and fostering exceptional partnerships between our different units in order to produce the best possible results for physicians. I would like to thank the medical community for giving their time so willingly and for their excellent advice," Robocath CEO Lucien Goffart stated. "I would also like to thank all our staff who have worked so hard to launch this new robotic platform and, in doing so, taken us one step further on our roadmap to greater commercial success.”
“Robotic technology is digitizating endovascular medicine. I’m delighted that we are now launching R-One+; this solution marks a major step forward in the digital transformation of the cathlab as we continue to work towards our goal of ensuring better care for patients and better protection for medical staff,” Robocath President/Founder Philippe Bencteux, M.D., said.
Founded in 2009 by Bencteux, Robocath designs, develops, and commercializes smart robotic solutions to treat cardiovascular diseases. As an active player in the digital evolution of the medical industry, its smart connected solutions aim to enhance hand gestures and make medical procedures safer. Robocath develops robotic solutions integrating a unique bionic technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. Robocath’s robotic solutions are designed to operate with precision and perform accurate movements, creating better interventional conditions. Thanks to their open architecture, they are all compatible with market-leading devices and cathlabs.
The company received the CE marking for R-One, its first robotic solution, in 2019. In a prospective, multicenter, non-randomized, single-arm clinical trial, R-One demonstrated safety and efficacy as it achieved more than 95% technical procedure success with no MACE (major adverse cardiovascular events). Currently R-One is used in Europe, Africa, and China. Based in Rouen, France, Robocath has more than 70 employees.